These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 6248185)

  • 41. Effect of clinical features on the association of estrogens and breast cancer.
    Horwitz RI; Stewart KR
    Am J Med; 1984 Feb; 76(2):192-8. PubMed ID: 6695946
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
    Colditz GA; Hankinson SE; Hunter DJ; Willett WC; Manson JE; Stampfer MJ; Hennekens C; Rosner B; Speizer FE
    N Engl J Med; 1995 Jun; 332(24):1589-93. PubMed ID: 7753136
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Menopause, postmenopausal estrogen preparations, and the risk of adult-onset asthma. A prospective cohort study.
    Troisi RJ; Speizer FE; Willett WC; Trichopoulos D; Rosner B
    Am J Respir Crit Care Med; 1995 Oct; 152(4 Pt 1):1183-8. PubMed ID: 7551368
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Postmenopausal hormone therapy and mammographic breast density.
    Marchesoni D; Driul L; Ianni A; Fabiani G; Della Martina M; Zuiani C; Bazzocchi M
    Maturitas; 2006 Jan; 53(1):59-64. PubMed ID: 15939560
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis.
    Smith NL; Heckbert SR; Lemaitre RN; Reiner AP; Lumley T; Weiss NS; Larson EB; Rosendaal FR; Psaty BM
    JAMA; 2004 Oct; 292(13):1581-7. PubMed ID: 15467060
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association of new-onset breast discomfort with an increase in mammographic density during hormone therapy.
    Crandall CJ; Karlamangla A; Huang MH; Ursin G; Guan M; Greendale GA
    Arch Intern Med; 2006 Aug 14-28; 166(15):1578-84. PubMed ID: 16908790
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Estrogen and the postmenopausal breast. Mammographic considerations.
    Peck DR; Lowman RM
    JAMA; 1978 Oct; 240(16):1733-5. PubMed ID: 691171
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Post-treatment change in serum estrone predicts mammographic percent density changes in women who received combination estrogen and progestin in the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.
    Ursin G; Palla SL; Reboussin BA; Slone S; Wasilauskas C; Pike MC; Greendale GA
    J Clin Oncol; 2004 Jul; 22(14):2842-8. PubMed ID: 15254051
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk factors for breast cancer in women undergoing mammography.
    Reuter KL; Baker SP; Krolikowski FJ
    AJR Am J Roentgenol; 1992 Feb; 158(2):273-8. PubMed ID: 1729780
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of hormone replacement therapy on mammographic findings.
    Bülbül NH; Ozden S; Dayicioglu V
    Arch Gynecol Obstet; 2003 Apr; 268(1):5-8. PubMed ID: 12673467
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lobular carcinoma in situ of the breast: clinical, pathologic, and mammographic features.
    Beute BJ; Kalisher L; Hutter RV
    AJR Am J Roentgenol; 1991 Aug; 157(2):257-65. PubMed ID: 1853802
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mammographic changes associated with postmenopausal hormone replacement therapy: a longitudinal study.
    Stomper PC; Van Voorhis BJ; Ravnikar VA; Meyer JE
    Radiology; 1990 Feb; 174(2):487-90. PubMed ID: 2136958
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Mammographic parenchymal pattern and risk of breast cancer (author's transl)].
    Hüppe JR
    Rofo; 1981 Jun; 134(6):638-42. PubMed ID: 6454623
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy. A report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center.
    N Engl J Med; 1974 Jan; 290(1):15-9. PubMed ID: 4357161
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The risk of breast cancer after estrogen and estrogen-progestin replacement.
    Bergkvist L; Adami HO; Persson I; Hoover R; Schairer C
    N Engl J Med; 1989 Aug; 321(5):293-7. PubMed ID: 2546079
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy--long-term follow-up of a Swedish cohort.
    Persson I; Yuen J; Bergkvist L; Schairer C
    Int J Cancer; 1996 Jul; 67(3):327-32. PubMed ID: 8707404
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Estrogen replacement therapy and benign breast disease.
    Trapido EJ; Brinton LA; Schairer C; Hoover R
    J Natl Cancer Inst; 1984 Nov; 73(5):1101-5. PubMed ID: 6092767
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influence of patterns of hormone replacement therapy use and mammographic density on breast cancer detection.
    Chiarelli AM; Kirsh VA; Klar NS; Shumak R; Jong R; Fishell E; Yaffe MJ; Boyd NF
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1856-62. PubMed ID: 17035392
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mammographic density, response to hormones, and breast cancer risk.
    Boyd NF; Melnichouk O; Martin LJ; Hislop G; Chiarelli AM; Yaffe MJ; Minkin S
    J Clin Oncol; 2011 Aug; 29(22):2985-92. PubMed ID: 21709206
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of long-term estrogen replacement therapy. II. Neoplasia.
    Hammond CB; Jelovsek FR; Lee KL; Creasman WT; Parker RT
    Am J Obstet Gynecol; 1979 Mar; 133(5):537-47. PubMed ID: 220875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.